- Q2 Results In-Line with Earnings Pre-Announcement Issued on July 6, 2020
- Ayr has Delivered Dramatic Improvements Across Key Financial Metrics Each Month Through July 2020
- As of July 2020, Operating at an Annual Revenue & Adjusted EBITDA Run-Rate of $181 Million and $77 Million, Respectively
- Generated $8.7 Million in Cash from Operations in Q2; Cash Balance Remains Strong with $17 Million at July 31, 2020
- Expanding Footprint to Three New States; Today Announcing a Binding Agreement Signed for Cultivation, Production and Dispensary Assets in Pennsylvania, and an Additional Two New Markets Anticipated to be Announced in Q3
- Announces the Appointment of New Executives and Board Member
TORONTO, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Ayr Strategies Inc. (CSE: AYR.A, OTCQX: AYRSF) (“Ayr” or the “Company”), a vertically-integrated cannabis multi-state operator (MSO), is reporting financial results for the three months ended June 30, 2020, as well as preliminary results for July 2020. The Company is also announcing that it has entered into an agreement to expand its footprint to include cultivation, production and dispensary assets in Pennsylvania. Unless otherwise noted, all results are presented in U.S. dollars.
“Our business has performed extremely well across market environments, and we enter the next phase of our corporate development in a position of even greater operational strength,” said Ayr CEO Jon Sandelman. “Over the past four months, we have driven consistent, material month-over-month improvements in our operations. We achieved monthly records for revenue, adjusted EBITDA and operating income in July, and we are currently operating at an exceptional $181 million and $77 million annual run rate for revenue and adjusted EBITDA, respectively. I am incredibly proud of our team’s hard work and the momentum we have generated; but I want to stress that we are just getting started.”
Financial Highlights ($ in millions, excl. margin items)
| Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | ||||||||||||||
| Revenue | $ | 11.7 | $ | 11.7 | $ | 10.2 | $ | 5.8 | $ | 9.8 | $ | 12.7 | $ | 15.1 | ||||||
| Gross Margin before Fair Value Adj. | 48.2% | 48.7% | 52.3% | 58.2% | 61.9% | 60.2% | 60.8% | |||||||||||||
| Adj. EBITDA | $ | 2.9 | $ | 3.0 | $ | 2.5 | $ | 0.8 | $ | 3.3 | $ | 5.0 | $ | 6.4 | ||||||
The preliminary July 2020 results are subject to change following completion of the company’s quarterly financial reporting process.
| Q1 2020 | Q2 2020 | % Change | |||||
| Revenue | $ | 33.6 | $ | 28.3 | (16)% | ||
| Gross Profit | $ | 20.3 | $ | 23.5 | 16% | ||
| Gross Profit before Fair Value Adj. | $ | 16.6 | $ | 17.1 | 3% | ||
| Operating Income/(Loss) | $ | (4.9) | $ | 1.0 | N/A | ||
| Net Income/(Loss) | $ | 1.6 | $ | (7.5) | N/A | ||
| Adj. EBITDA | $ | 8.4 | $ | 9.1 | 8% | ||
Sandelman continued: “Our monthly revenue improvements have been driven by exceptional retail growth in Nevada, where dispensary sales have grown by nearly 20% month-over-month in July. Gross margins have also benefitted from our expanded cultivation capacity in the state, which has driven higher levels of vertical integration in our dispensaries. The additional dispensary licenses we were recently granted in Clark County and Henderson will allow us to deepen our presence and reach an even greater number of patients and customers, and we are targeting opening our new Clark County dispensary before year end. In Massachusetts, our wholesale business has continued to ramp up due to our expanded cultivation capacity and strong demand resulting from new recreational dispensaries coming online every month. Our two medical dispensaries have also nearly doubled in revenue from pre-COVID levels. Our success in the Massachusetts and Nevada markets, especially amid a challenging operating environment, demonstrates the power and discipline of our strategy as we take our approach into new markets.”
Acquisition Overview
Speaking on Ayr’s proposed acquisition, Sandelman commented: “Our entry into new markets will build on the successful operational foundation we have established over the last 12 months, where we drove exceptional organic growth across our business. Moreover, we did so while simultaneously building the strong 600+ person team, culture, and financial and operational control framework we have today.
“The transaction we are announcing today and the additional transactions we will announce through the rest of this quarter are just the first step to expanding our footprint and firmly establishing Ayr as a top MSO – not only in terms of revenue, adjusted EBITDA, operating income and cash flow generation, but also in terms of presence across the industry’s most relevant markets. We believe today’s announced acquisition in Pennsylvania, along with the two expected additional markets to be announced later this quarter, will integrate efficiently into our established platform as a result of the strong foundation and scalable systems we have built. As we expand our footprint, we intend to repeat the playbook of excellent operations and successful greenfield project development that we have established and proven over the last 12 months.
“Similar to our prior acquisitions, we are bringing on exceptional teams to add to our deep talent pool, and we are purchasing these assets at very attractive levels of forward adjusted EBITDA for a combination of $27 million cash, $15 million stock and $15 million vendor notes. We have also been working diligently with strong institutional financing partners to seek to ensure that our future expansion plans are fully financed. We are extremely pleased that the debt markets have been highly receptive to Ayr’s strong credit profile. We are proud of the platform we have built and believe this is the beginning of an even stronger growth cycle for Ayr.
“Finally, I am thrilled to welcome a few new members to the Ayr team. Glenn Isaacson, who currently serves as Vice Chairman at Cushman & Wakefield, is joining our Board of Directors. He is also on the board of the American Foundation for AIDS Research. Glenn’s experience will prove invaluable and we look forward to leveraging his expertise as we continue to expand our footprint. Further, Megan Kulick has joined as our new Head of Investor Relations; she is a Wall Street veteran who also brings great cannabis experience. Karen Rinaldi has been promoted to our Head of Human Resources, a role that has become incredibly important as we have grown to over 600 employees and counting. We are excited to have these key new members of the team on board.”
| Market Highlights | Pennsylvania | |
| Population (m) | 12.8 | |
| Legal Status | Medical | |
| License Issuance | Limited | |
| Penetration Rate (%)1 | 2.9% | |
| # of Active Dispensaries | 89 | |
| # of Cultivators & Processors | 32 | |
1 Penetration rate is calculated as current number of patients in a respective state divided by total state population.
Pennsylvania
Ayr has reached an agreement to acquire and develop six retail dispensaries and a significant cultivation and production footprint in a limited license state for total consideration of $57 million. The PA market is undersupplied with high barriers to entry and potential for substantial growth, as it has only 32 grower processor licenses and 198 dispensary permits to serve a rapidly growing medical patient base.
Ayr plans to acquire the membership interests in a licensed operator which includes a 143,000 ft² cultivation and processing facility with the initial construction phases comprising 45,000 ft² nearly complete. The 13-acre site provides ample room for further expansion even beyond the existing 143,000 ft² facility. The licensed operator also has the right to operate six dispensaries poised to open in excellent retail locations, most of which are clustered in the Pittsburgh and Philadelphia region. Three of these dispensaries are expected to open by January 2021. The licensed operator also has a strong research program in collaboration with a local medical school. The agreement, which is reflected in a binding term sheet, is subject to, among other things, the satisfactory completion of due diligence, the receipt of required regulatory approvals and the absence of a material adverse change.
Operational Highlights
As a reminder, Nevada regulators limited all cannabis sales to delivery-only beginning March 21, 2020, with curbside pick-up approved on May 1st and in-store sales on May 9th. In Massachusetts, regulators restricted adult use cannabis sales beginning March 24, 2020, with adult use sales commencing on May 25th.
Nevada Results
- July average daily revenues were over $300k; daily transaction volumes over 4,360, with an average ticket of $71 per transaction
- Recently awarded two additional dispensary licenses in the greater Las Vegas market—one in Clark County and one in Henderson—and aim to open the additional Clark County dispensary this year
Massachusetts Results
- July average daily retail revenues are currently over $56k; daily transaction volumes over 350, with an average ticket of $162 per transaction
- Selling to 48 of the state’s 67 dispensaries, with valuable inventory to sell into the state’s growing recreational market
- Wholesale revenues have ramped to over $3.4 Million in July, reflecting growth of over 30% from levels at the start of 2020
Cultivation Expansions
- In Massachusetts, Ayr has completed several months of harvests from its cultivation expansion, resulting in strong inventories available to address pent-up demand for adult use sales
- The new Massachusetts cultivation facility is producing excellent results, with THC levels up to 30%, and improved gross margins in the state of approximately 70% in Q2 from the low 60% range in Q1
- In Nevada, product from Ayr’s cultivation expansion arrived in stores in June, allowing for internally sourced product to increase from 25% in Q1 to over 40% in Q2
- Nevada gross margin increased as a result, to approximately 60% in Q2 from 44% in Q1
Conference Call
Ayr CEO Jonathan Sandelman, COO Jennifer Drake and CFO Brad Asher will host the conference call, followed by a question and answer period.
Conference Call Date: Thursday, August 27, 2020
Time: 8:30 a.m. Eastern time
Toll-free dial-in number: (877) 282-0546
International dial-in number: (270) 215-9898
Conference ID: 5578887
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Investor Relations at (949) 574-3860.
The conference call will be broadcast live and available for replay here.
A telephonic replay of the conference call will also be available after 11:30 a.m. Eastern time on the same day through September 3, 2020.
Toll-free replay number: (855) 859-2056
International replay number: (404) 537-3406
Replay ID: 5578887
Financial Statements
Certain financial information reported in this news release is extracted from Ayr’s financial statements as at and for the three and six month periods ended June 30, 2020. These results presented herein are preliminary and subject to change. Ayr will file its interim financial statements on SEDAR shortly. All such financial information contained in this news release is qualified in its entirety by reference to such financial statements.
Definition and Reconciliation of Non-IFRS Measures
The Company reports certain non-IFRS measures that are used to evaluate the performance of its businesses and the performance of their respective segments, as well as to manage their capital structures. As non-IFRS measures generally do not have a standardized meaning, they may not be comparable to similar measures presented by other issuers. Securities regulators require such measures to be clearly defined and reconciled with their most comparable IFRS measure.
The Company references non-IFRS measures and cannabis industry metrics in this document and elsewhere. Non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these are provided as additional information to complement those IFRS measures by providing further understanding of the results of the operations of the Company from management’s perspective. Accordingly, these measures should not be considered in isolation, nor as a substitute for analysis of the Company’s financial information reported under IFRS. Non-IFRS measures used to analyze the performance of the Company’s businesses include “adjusted EBITDA.”
The Company believes that these non-IFRS financial measures provide meaningful supplemental information regarding the Company’s performances and may be useful to investors because they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making. These financial measures are intended to provide investors with supplemental measures of the Company’s operating performances and thus highlight trends in the Company’s core businesses that may not otherwise be apparent when solely relying on the IFRS measures.
Adjusted EBITDA
“Adjusted EBITDA” represents income (loss) from operations, as reported, before interest and tax, adjusted to exclude extraordinary items, non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, the adjustments for the accounting of the fair value of biological assets and the incremental costs to acquire cannabis inventory in a business combination, and further adjusted to remove acquisition related costs.
A reconciliation of how Ayr calculates adjusted EBITDA is provided below. Additional reconciliations of adjusted EBITDA and other disclosures concerning non-IFRS measures will be provided in our MD&A for the 3 months ended June 30, 2020. As well, the Company reminds you that adjusted EBITDA is a non-IFRS measure.
Forward-Looking Statements
Certain information contained in this news release may be forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are often, but not always, identified by the use of words such as “target”, “expect”, “anticipate”, “believe”, “foresee”, “could”, “would”, “estimate”, “goal”, “outlook”, “intend”, “plan”, “seek”, “will”, “may”, “tracking”, “pacing” and “should” and similar expressions or words suggesting future outcomes. This news release includes forward-looking information and statements pertaining to, among other things, Ayr’s future growth plans. Numerous risks and uncertainties could cause the actual events and results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements, including, but not limited to: anticipated strategic, operational and competitive benefits may not be realized; events or series of events, including in connection with COVID-19, may cause business interruptions; required regulatory approvals may not be obtained; acquisitions may not be able to be completed on satisfactory terms or at all; and Ayr may not be able to raise additional debt or equity capital. Among other things, Ayr has assumed that its businesses will operate as anticipated, that it will be able to complete acquisitions on reasonable terms, and that all required regulatory approvals will be obtained on satisfactory terms and within expected time frames. In particular, there can be no assurance that we will complete the acquisition in Pennsylvania or enter into agreements with respect to other acquisitions.
2020 estimates and assumptions involve known and unknown risks and uncertainties that may cause actual results to differ materially. While Ayr believes there is a reasonable basis for these assumptions, such estimates may not be met. These estimates represent forward-looking information. Actual results may vary and differ materially from the estimates.
Assumptions
Forward-looking information in this subject to the assumptions and risks as described in our MD&A for June 30, 2020. For more information about the Company’s 2020 operations and outlook, please view Ayr’s corporate presentation posted in the Investors section of the Company’s website at www.ayrstrategies.com. As well, we remind you that adjusted EBITDA is a non-IFRS measure. Additional reconciliations and other disclosures concerning non-IFRS measures will be provided in our MD&A for the 3 and 6 months ended June 30, 2020.
About Ayr Strategies Inc.
Ayr Strategies (“Ayr”) is an expanding vertically integrated, U.S. multi-state cannabis operator, focusing on high-growth markets. With anchor operations in Massachusetts and Nevada, the company cultivates and manufactures branded cannabis products for distribution through its network of retail outlets and through third-party stores. Ayr strives to enrich and enliven consumers’ experience every day – helping them to live their best lives, elevated.
Ayr’s leadership team brings proven expertise in growing successful businesses through disciplined operational and financial management, and is committed to driving positive impact for customers, employees and the communities they touch. For more information, please visit www.ayrstrategies.com.
Company Contact:
Jennifer Drake, COO
T: (212) 299-7606
Investor Relations Contact:
Sean Mansouri, CFA or Cody Slach
Gateway Investor Relations
T: (949) 574-3860
Email: ayr@gatewayir.com
Ayr Strategies Inc. (formerly, Cannabis Strategies Acquisition Corp.)
Unaudited Condensed Interim Consolidated Statements of Financial Position
(Expressed in United States Dollars)
| As at | |||||
| June 30, 2020 | December 31, 2019 | ||||
| $ | $ | ||||
| ASSETS | |||||
| Current | |||||
| Cash and cash equivalents | 15,986,515 | 8,403,196 | |||
| Accounts receivable | 1,935,036 | 2,621,239 | |||
| Due from related parties | 85,000 | 85,000 | |||
| Inventory | 20,419,223 | 13,718,840 | |||
| Biological assets | 9,239,566 | 2,935,144 | |||
| Prepaid expenses and other current assets | 3,168,822 | 2,163,329 | |||
| 50,834,162 | 29,926,748 | ||||
| Non-current | |||||
| Property, plant and equipment | 39,487,778 | 37,152,861 | |||
| Intangible assets | 183,044,803 | 189,802,136 | |||
| Right-of-use assets | 11,399,736 | 12,315,417 | |||
| Goodwill | 84,837,304 | 84,837,304 | |||
| Equity investments | 477,961 | 427,399 | |||
| Other assets | 753,394 | 638,394 | |||
| Total assets | 370,835,138 | 355,100,259 | |||
| LIABILITIES | |||||
| Current | |||||
| Trade payables | 7,907,441 | 6,806,053 | |||
| Accrued liabilities | 5,829,850 | 5,123,865 | |||
| Lease obligations - current portion | 939,602 | 1,087,835 | |||
| Purchase consideration payable | 6,290,897 | 9,831,700 | |||
| Income tax payable | 13,470,358 | 5,202,943 | |||
| Debts payable - current portion | 8,247,133 | 6,628,843 | |||
| 42,685,281 | 34,681,239 | ||||
| Non-current | |||||
| Deferred tax liabilities | 42,429,247 | 41,077,761 | |||
| Warrant liability | 26,088,841 | 36,874,124 | |||
| Lease obligations - non-current portion | 12,607,312 | 13,033,310 | |||
| Contingent consideration | 23,376,154 | 22,656,980 | |||
| Debts payable - non-current portion | 33,839,333 | 37,366,818 | |||
| Accrued interest payable | 1,513,866 | 815,662 | |||
| Total liabilities | 182,540,034 | 186,505,894 | |||
| SHAREHOLDERS' EQUITY (DEFICIENCY) | |||||
| Share capital | 385,975,933 | 382,210,006 | |||
| Treasury stock | (552,911 | ) | (245,469 | ) | |
| Contributed surplus | 50,127,987 | 28,879,225 | |||
| Accumulated other comprehensive income | 4,217,744 | 3,265,610 | |||
| Deficit | (251,473,649 | ) | (245,515,007 | ) | |
| Total shareholders' equity | 188,295,104 | 168,594,365 | |||
| Total liabilities and shareholders' equity | 370,835,138 | 355,100,259 | |||
Ayr Strategies Inc. (formerly, Cannabis Strategies Acquisition Corp.)
Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss
(Expressed in United States Dollars)
| Three Months Ended | Six Months Ended | ||||||||||
| June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | ||||||||
| $ | $ | $ | $ | ||||||||
| Revenues, net of discounts | 28,310,633 | 10,823,206 | 61,863,313 | 10,823,206 | |||||||
| Cost of goods sold before biological asset adjustments | 11,219,545 | 4,923,766 | 28,130,267 | 4,923,766 | |||||||
| Gross profit before fair value adjustments | 17,091,088 | 5,899,440 | 33,733,046 | 5,899,440 | |||||||
| Fair value adjustment on sale of inventory | (9,328,081 | ) | (4,696,472 | ) | (16,331,570 | ) | (4,696,472 | ) | |||
| Unrealized gain on biological asset transformation | 15,706,510 | 2,479,803 | 26,332,388 | 2,479,803 | |||||||
| Gross profit | 23,469,517 | 3,682,771 | 43,733,864 | 3,682,771 | |||||||
| Expenses | |||||||||||
| General and administrative | 8,958,708 | 3,084,872 | 17,764,940 | 3,084,872 | |||||||
| Sales and marketing | 409,245 | 236,711 | 943,844 | 236,711 | |||||||
| Depreciation | 601,351 | 138,649 | 1,125,982 | 138,649 | |||||||
| Amortization | 2,998,667 | 1,387,977 | 5,997,333 | 1,387,977 | |||||||
| Stock-based compensation | 9,103,459 | 4,520,138 | 21,248,762 | 4,520,138 | |||||||
| Acquisition expense | 368,930 | 2,591,312 | 497,309 | 4,132,400 | |||||||
| Total expenses | 22,440,360 | 11,959,659 | 47,578,170 | 13,500,747 | |||||||
| Income (Loss) from operations | 1,029,157 | (8,276,888 | ) | (3,844,306 | ) | (9,817,976 | ) | ||||
| Other (expense) income | |||||||||||
| Share of loss (income) on equity investments | (8,013 | ) | 106,911 | (23,138 | ) | 106,911 | |||||
| Foreign exchange | 191 | (35,083 | ) | (2,619 | ) | (18,368 | ) | ||||
| Unrealized (loss) gain - changes to fair value of financial liabilities | (2,861,022 | ) | (26,621,554 | ) | 8,888,849 | (162,434,128 | ) | ||||
| Interest expense | (752,614 | ) | (586,389 | ) | (1,519,577 | ) | (586,389 | ) | |||
| Interest income | 26 | 137,302 | - | 364,518 | |||||||
| Other | 44,785 | (12,212 | ) | 161,050 | (12,212 | ) | |||||
| Total other (expense) income | (3,576,647 | ) | (27,011,025 | ) | 7,504,565 | (162,579,668 | ) | ||||
| (Loss) Income before income tax | (2,547,490 | ) | (35,287,913 | ) | 3,660,259 | (172,397,644 | ) | ||||
| Current tax | (4,223,419 | ) | (1,430,813 | ) | (8,267,415 | ) | (1,430,813 | ) | |||
| Deferred tax | (742,799 | ) | 932,901 | (1,351,486 | ) | 932,901 | |||||
| Net loss | (7,513,708 | ) | (35,785,825 | ) | (5,958,642 | ) | (172,895,556 | ) | |||
| Foreign currency translation adjustment | (823,634 | ) | (1,677,876 | ) | 952,134 | (880,469 | ) | ||||
| Net loss and comprehensive loss | (8,337,342 | ) | (37,463,701 | ) | (5,006,508 | ) | (173,776,025 | ) | |||
| Basic and diluted loss per share | (0.28 | ) | (2.18 | ) | (0.22 | ) | (20.94 | ) | |||
| Weighted average number of shares outstanding (basic and diluted) | 27,241,386 | 16,440,042 | 27,065,654 | 8,256,123 | |||||||
Ayr Strategies Inc. (formerly, Cannabis Strategies Acquisition Corp.)
Unaudited Condensed Interim Consolidated Statements of Cash Flows
(Expressed in United States Dollars)
| Six Months Ended | ||||
| June 30, 2020 | June 30, 2019 | |||
| $ | $ | |||
| Operating activities | ||||
| Net loss | (5,958,642 | ) | (172,895,556 | ) |
| Adjustments for: | ||||
| Acquisition costs associated with financing activities | - | 129,236 | ||
| Net unrealized (gain) loss on changes in the fair value of financial liabilities | (8,888,849 | ) | 162,434,128 | |
| Stock-based compensation | 21,248,762 | 4,520,138 | ||
| Depreciation | 2,017,982 | 257,245 | ||
| Amortization on intangible assets | 6,757,333 | 1,387,977 | ||
| Share of loss on equity investments | 23,138 | (106,911 | ) | |
| Fair value adjustment on sale of inventory | 16,331,570 | 4,696,472 | ||
| Unrealized gain on biological asset transformation | (26,332,388 | ) | (2,479,803 | ) |
| Deferred tax expense (benefit) | 1,351,486 | (932,901 | ) | |
| Interest accrued | 698,204 | 264,770 | ||
| Interest income | - | (364,518 | ) | |
| Changes in non-cash operations, net of business acquisition: | ||||
| Accounts receivable | 686,203 | 568,471 | ||
| Inventory and biological assets | (3,003,987 | ) | 797,064 | |
| Prepaid expenses and other assets | (1,120,493 | ) | (2,255,026 | ) |
| Trade payables | 3,265,691 | 2,455,857 | ||
| Accrued liabilities | 705,985 | 772,978 | ||
| Income tax payable | 8,267,415 | 1,430,813 | ||
| Cash provided by operating activities | 16,049,410 | 680,434 | ||
| Investing activities | ||||
| Transfer of restricted cash and short term investments held in escrow and interest income | - | 100,048,761 | ||
| Purchase of property, plant and equipment | (5,601,523 | ) | (160,254 | ) |
| Deferred underwriters commission paid | - | (3,457,154 | ) | |
| Cash paid for business combinations, net of cash acquired | - | (74,714,171 | ) | |
| Payments for interests in equity accounted investments | (73,700 | ) | - | |
| Advances from related corporation | - | (1,520,909 | ) | |
| Cash (used in) provided by investing activities | (5,675,223 | ) | 20,196,273 | |
| Financing activities | ||||
| Redemption of Class A shares | - | (7,519 | ) | |
| Repayments of debts payable | (1,909,195 | ) | (539,579 | ) |
| Repayments of lease obligations (principal portion) | (574,231 | ) | (43,878 | ) |
| Repurchase of Subordinate Voting Shares | (307,442 | ) | - | |
| Cash used in financing activities | (2,790,868 | ) | (590,976 | ) |
| Net increase in cash | 7,583,319 | 20,285,731 | ||
| Effect of foreign currency translation | - | (2,466,655 | ) | |
| Cash and cash equivalents, beginning of the period | 8,403,196 | 109,952 | ||
| Cash and cash equivalents, end of the period | 15,986,515 | 17,929,028 | ||
| Supplemental disclosure of cash flow information: | ||||
| Interest paid during the period | 1,287,017 | 321,619 | ||
| Taxes paid during the period | - | 111,607 | ||
Ayr Strategies Inc. (formerly, Cannabis Strategies Acquisition Corp.)
Unaudited Condensed Interim Consolidated Adjusted EBITDA Reconciliation
(Expressed in United States Dollars)
| Three Months ended June 30, | Six Months ended June 30, | ||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||
| Income (Loss) from operations | 1,029,157 | (8,276,888 | ) | (3,844,306 | ) | (9,817,976 | ) | ||||
| Non-cash items accounting for biological assets and inventory | |||||||||||
| Fair value adjustment on sale of inventory | 9,328,081 | 4,696,472 | 16,331,570 | 4,696,472 | |||||||
| Unrealized gain on biological asset transformation | (15,706,510 | ) | (2,479,803 | ) | (26,332,388 | ) | (2,479,803 | ) | |||
| (6,378,429 | ) | 2,216,669 | (10,000,818 | ) | 2,216,669 | ||||||
| Interest | 253,770 | - | 466,191 | - | |||||||
| Depreciation and amortization (from statement of cash flows) | 4,507,139 | 1,645,222 | 8,775,315 | 1,645,222 | |||||||
| Acquisition costs | 368,930 | 2,591,312 | 497,309 | 4,132,400 | |||||||
| Stock-based compensation, non-cash | 9,103,459 | 4,520,138 | 21,248,762 | 4,520,138 | |||||||
| Other1 | 239,352 | 312,801 | 420,464 | 312,801 | |||||||
| 14,472,650 | 9,069,473 | 31,408,041 | 10,610,561 | ||||||||
| Adjusted EBITDA (non-IFRS) | 9,123,378 | 3,009,254 | 17,562,917 | 3,009,254 | |||||||
| 1 Other adjustments made to exclude the impact of non-recurring items. | |||||||||||